Role of Coagulation Factors in Hepatocellular Carcinoma: A Literature Review

Overview

Journal Life (Basel)

Date 2025 Jan 25

PMID 39859975

Authors

Azeem Azam

Aleksandra Klisic

Filiz Mercantepe

Hamza Faseeh

Tolga Mercantepe

Saira Rafaqat

Affiliations

Soon will be listed here.

Abstract

Hepatocyte carcinoma (HCC) is a globally prevalent neoplasm with profound effects on morbidity and mortality rates. This review summarizes the complex interactions between coagulation abnormalities and the pathophysiological mechanisms underlying HCC. Essential coagulation biomarkers, such as P-selectin, thrombomodulin, d-dimer, prothrombin, and von Willebrand factor, are reviewed for their diagnostic, prognostic, and therapeutic significance. The contribution of these biomarkers to tumor progression, metastatic spread, and patient prognosis is highlighted through a synthesis of contemporary research findings. In addition, this review highlights the underlying mechanisms linking coagulation pathways to HCC pathogenesis and explores potential therapeutic targets. An integrative perspective on the role of coagulation markers in HCC may improve clinical management strategies for patients affected by this malignancy.

References

Pereyra D, Mandorfer M, Santol J, Gregory L, Koeditz C, Ortmayr G . Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma. Ann Surg Oncol. 2024; 31(10):6526-6536. DOI: 10.1245/s10434-024-15618-w. View

Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P . The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics. 2014; 106:99-112. DOI: 10.1016/j.jprot.2014.04.021. View

Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F . Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008; 48(6):1000-7. DOI: 10.1016/j.jhep.2008.03.009. View

Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S . von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. United European Gastroenterol J. 2018; 6(9):1401-1409. PMC: 6206538. DOI: 10.1177/2050640618779660. View

Li S, Wei X, He J, Tian X, Yuan S, Sun L . Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother. 2018; 105:83-94. DOI: 10.1016/j.biopha.2018.05.119. View

Weitz J, Fredenburgh J, Eikelboom J . A Test in Context: D-Dimer. J Am Coll Cardiol. 2017; 70(19):2411-2420. DOI: 10.1016/j.jacc.2017.09.024. View

Hernandez-Pando R, Kershenobich D, Rodriguez-Fragoso L . Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma. Toxicology. 2001; 161(1-2):13-23. DOI: 10.1016/s0300-483x(00)00404-2. View

Boron M, Hauzer-Martin T, Keil J, Sun X . Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures. TH Open. 2022; 6(3):e194-e212. PMC: 9273331. DOI: 10.1055/a-1801-2055. View

Shamimi-Noori S, Gonsalves C, Shaw C . Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. Semin Intervent Radiol. 2017; 34(2):145-166. PMC: 5453777. DOI: 10.1055/s-0037-1602712. View

10.

Shindoh J, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Yamashiki N . Thrombotic microangiopathy after living-donor liver transplantation. Am J Transplant. 2011; 12(3):728-36. DOI: 10.1111/j.1600-6143.2011.03841.x. View

11.

Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin C . Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2017; 43(1):13-25. DOI: 10.1007/s00261-017-1209-1. View

12.

Iwako H, Tashiro H, Amano H, Tanimoto Y, Oshita A, Kobayashi T . Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2012; 19(9):2888-96. DOI: 10.1245/s10434-012-2338-y. View

13.

Flores B, Trivedi H, Robson S, Bonder A . Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2018; 3(3). PMC: 6136435. DOI: 10.15761/JTS.1000182. View

14.

Qian X, Cai J, Qi Q, Han J, Zhu X, Xia R . Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway. Heliyon. 2023; 9(6):e16696. PMC: 10248116. DOI: 10.1016/j.heliyon.2023.e16696. View

15.

Jing W, Peng R, Zhu M, Lv S, Jiang S, Ma J . Differential Expression and Diagnostic Significance of Pre-Albumin, Fibrinogen Combined with D-Dimer in AFP-Negative Hepatocellular Carcinoma. Pathol Oncol Res. 2019; 26(3):1669-1676. DOI: 10.1007/s12253-019-00752-8. View

16.

Okimoto S, Tashiro H, Iwako H, Kuroda S, Kobayashi T, Hinoi T . Antithrombin attenuates the progression of hepatocellular carcinoma by regulating neutrophil/interleukin-8 signaling. Hepatol Res. 2020; 50(11):1284-1296. DOI: 10.1111/hepr.13558. View

17.

Fang P, Du L, Cai D . Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2020; 99(12):e19461. PMC: 7220415. DOI: 10.1097/MD.0000000000019461. View

18.

Tokuyasu N, Amisaki M, Hanaki T, Murakami Y, Morimoto M, Uchinaka E . Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma. Yonago Acta Med. 2021; 64(2):168-175. PMC: 8128657. DOI: 10.33160/yam.2021.05.007. View

19.

Chen S, Morine Y, Tokuda K, Yamada S, Saito Y, Nishi M . Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway. Int J Oncol. 2021; 59(2). PMC: 8253588. DOI: 10.3892/ijo.2021.5239. View

20.

Morrissey J . Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol. 2004; 79(2):103-8. DOI: 10.1532/ijh97.03167. View